Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Data on Endometriosis Discussed by Researchers at AbbVie (Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 06:05pm CET

Data on Endometriosis Discussed by Researchers at AbbVie (Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women)

By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Uterine Diseases and Conditions - Endometriosis have been published. According to news reporting originating in North Chicago, Illinois, by NewsRx journalists, research stated, "To estimate the prevalence of diagnosed endometriosis (DE) in women in the United States and assess the associated symptomatic burden. An online, cross-sectional survey of women aged 18-49 years was conducted from August 6, 2012, through November 14, 2012."

The news reporters obtained a quote from the research from AbbVie, "Survey data (weighted by age, race, education, income, geographical distribution, and propensity score) were used to estimate the prevalence and symptomatic burden of DE in women in the United States. Weighted logistic regressions were used to assess differences in symptom burden between women with and without endometriosis. The prevalence of DE was estimated at 6.1% (2,922 of 48,020 women surveyed); 52.7% of women were 18-29 years of age when they were diagnosed with endometriosis. Most (86.2%) women experienced symptoms before diagnosis. More women with (vs. without) DE had menstrual pelvic pain/ cramping (52.7 vs. 45.2%), non-menstrual pelvic pain/cramping (36.7 vs. 14.3%), infertility (11.6 vs. 3.4%), and dyspareunia (29.5 vs. 13.4%). Women with endometriosis were also more likely to report severe symptoms (OR (95% CI) 2.7 (2.3-3.1) for menstrual pelvic pain/cramping, 2.2 (1.7-2.9) for non-menstrual pelvic pain/cramping, and 2.4 (1.8-3.2) for dyspareunia)."

According to the news reporters, the research concluded: "The prevalence of DE among US women is notable, and affected women experience a substantial symptom burden."

For more information on this research see: Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women. Gynecologic and Obstetric Investigation, 2017;82(5):453-461. Gynecologic and Obstetric Investigation can be contacted at: Karger, Allschwilerstrasse 10, Ch-4009 Basel, Switzerland. (Karger - www.karger.com/; Gynecologic and Obstetric Investigation - content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223845)

Our news correspondents report that additional information may be obtained by contacting A.M. Soliman, AbbVie Inc, Hlth Econ & Outcomes Res, North Chicago, IL 60064, United States (see also Uterine Diseases and Conditions - Endometriosis).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1159/000452660. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: North Chicago, Illinois, United States, North and Central America, Female Urogenital Diseases and Conditions, Pelvic Pain, Diagnostics and Screening, Female Genital Diseases and Conditions, Physiological Sexual Dysfunction, Uterine Diseases and Conditions, Women's Health, Endometriosis, Dyspareunia, AbbVie.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBVIE
12:05a Wall Street falls as investors fret about tax bill passage
12/14 ABBVIE : Recent Data from A.J. Epstein and Co-Authors Highlight Findings in Endo..
12/14 ABBVIE : IMBRUVICA Data Provide Insights Into Its Potential Treatment Benefits
12/14 ABBVIE : Announces Phase 3 Study of VENCLEXTA VENCLYXTO in Combination with Ritu..
12/13 ABBVIE : Roche boast stellar PhIII leukemia data for a breakthrough combo with b..
12/12 ABBVIE : IMBRUVICA Pooled Analysis Suggests Benefit in Progression-Free Survival..
12/12 ABBVIE : IMBRUVICA Patient-Reported Outcomes Data Detail Long-Term Improvement i..
12/12 ABBVIE : Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetocl..
12/12 ABBVIE : 36 Saudis graduate from AbbVie’s pharma training program
12/11 ABBVIE : IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatme..
More news
News from SeekingAlpha
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/14 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : AbbVie And Roche Stellar Data, Aduro Pull..
12/13 ARGENX : This ASH Winner Has Further Upside Ahead
12/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 13, 2017
12/13 Why Tech Still Looks So Attractive
Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,67%
P/E ratio 2017 20,99
P/E ratio 2018 16,55
EV / Sales 2017 6,50x
EV / Sales 2018 5,75x
Capitalization 155 B
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 99,9 $
Spread / Average Target 2,6%
EPS Revisions
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE53.23%155 185
MERCK KGAA-10.38%13 853
CONVATEC GROUP-10.13%5 439